Uscom Limited · ASX:UCM

Uscom — Investor Presentation (February 2014)

28 slides from Uscom's investor presentation, Feb 20, 2014

  1. Slide 1: The Cardiovascular Device Company: Investment overview

    For personal use only The Cardiovascular Device Company Premium non-invasive cardiovascular monitoring for global medical markets Rob Phillips Executive Chairman and Chief Executive Officer Investment overview 20th February 2014

  2. Slide 2: Disclaimer

    Disclaimer For personal use only • This Investor Presentation contains confidential information regarding Uscom and its affiliates. The information contained in this Investor Presentation is believed to be reliable. No assurance is given as to the accuracy or completeness of such information This In

  3. Slide 3: Message

    Message For personal use only “Uscom is a Company on the move. Uscom owns two real, practice changing cardiovascular devices selling into massive global medical markets, and is focused on sales, distribution and revenue.” 3 The measure of life www.uscom.com.au

  4. Slide 4: Uscom – Two breakthrough devices

    Uscom – Two breakthrough devices For personal use only Real products, real science and real value • Validation • Patent protected • Regulatory Approval – both products CE, FDA • Revenue Generating – both products • Hypertension, Heart failure, Sepsis, ICU, ED, Anaesthesia, Paediatric markets – estab

  5. Slide 5: Market: Estimated BP device market

    Market For personal use only Estimated BP device market “the global blood pressure monitoring testing market was valued at USD $1.7b in 2012 and is estimated to reach a market worth USD 3.7b in 2019, at a CAGR of 11.5% from 2013 to 2019.” 5 The measure of life

  6. Slide 6: USCOM Market

    USCOM Market For personal use only Estimated USCOM Market “the global physiology monitoring market was valued at USD $1.3b in 2012 with an estimated CAGR of 7.6% from 2013 to 2019.” 6 The measure of life

  7. Slide 7: Uscom – Two markets - $3b

    Uscom – Two markets - $3b For personal use only Real clinical solutions, real markets $3b USD Combined Market Hypertension Heart failure, Clinical central BP Sepsis, Fluid 7 The measure of life www.uscom.com.au

  8. Slide 8: Our Business

    Our Business For personal use only • Uscom (ASX: UCM) makes and sells two FDA/CE/TGA approved cardiovascular monitoring products – USCOM 1A and the Uscom BP+ • Uscom products - two premium cardiovascular devices measuring cardiac output and blood pressure. • USCOM – Cardiac Output • Customers are ho

  9. Slide 9: Ultra-Sound Cardiac Monitor (USCOM 1A)

    Ultra-Sound Cardiac Monitor (USCOM 1A) For personal use only Non invasive, accurate, compact technology platform solution Accurate cardiac output Works with all other hospital equipment Cardiac stroke volume Systemic vascular Intuitive touch screen resistance Heart rate Real time data Left + right h

  10. Slide 10: USCOM – Sector leading science

    USCOM – Sector leading science For personal use only 350+ Peer reviewed publications and presentations Emergency, Pediatrics, Cardiac transplantation, Electrophysiology, Heart Failure, Emergency transport, Anesthesia, Liver transplantation, ICU, Septic shock, Pre- eclampsia, Pulmonary hypertension,

  11. Slide 11: USCOM – Standard of Care!

    USCOM – Standard of Care! For personal use only “USCOM has changed the way I look at the cardiovascular status of my patients. It’s part of the initial shock evaluation and monitored regularly thereafter; before and after any haemodynamic intervention. Haemodynamics with USCOM numbers are an integra

  12. Slide 12: USCOM – New Distributor!

    USCOM – New Distributor! For personal use only New 3 year, $2.35m AUD distribution deal Combined marketing resources Combined Doppler monitoring products Hemodynamics. Fluid. Innovation. 12 The measure of life www.uscom.com.au

  13. Slide 13: Uscom Central BP+ Monitor

    Uscom Central BP+ Monitor For personal use only New Wave Supra-systolic Oscillometry Central Blood Pressure and Pulse Pressure Wave Analysis FDA and CE approvals Home or clinical use Supra-systolic PPW Analysis Central BP+ Results in Reliable and 30 seconds accurate No training Central and required

  14. Slide 14: Why cBP? Best BP method

    Why ? For personal use only cBP Best BP method Latest research - University of Cambridge identifies BP+ most clinically applicable cBP monitor! 14 The measure of life

  15. Slide 15: Why BP+? Best cBP device

    Why ? For personal use only Latest Research - University of Cambridge identifies BP+ most clinically applicable cBP monitor! BP+ Best cBP device McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson AB. Central blood pressure: current evidence and clinical importance. Euro Heart J 2014;doi10.1

  16. Slide 16: Experienced management team

    Experienced management team For personal use only Rob Phillips • Founder and inventor of the USCOM1A Executive Chairman & CEO • Raised multiple rounds of capital • Recognised leader and innovator in the field of non-invasive cardiovascular monitoring with multiple peer review papers • Detailed knowl

  17. Slide 17: Milestones – Building Value

    Milestones – Building Value For personal use only ✓ • Patented USCOM concept ✓ • Built the USCOM device ✓ • Achieved global regulatory ✓ • Validated USCOM technology ✓ • Global sales and brand recognition ✓ • Widespread KOL support ✓ • 650 units world wide ($11m+ revenue total) ✓ • Standards of care

  18. Slide 18: Milestones – Building Value

    Milestones – Building Value For personal use only ✓ • Consolidated operations - 2011 ✓ • Controlled cash consumption - build toward global distribution partnership 2012 ✓ • Build science to “must have” status – BUSH sepsis protocol ✓ • Two product Company – Pulsecor acquisition 2013 ✓ • Strategic di

  19. Slide 19: Shareholder and financial snapshot

    Shareholder and financial snapshot For personal use only ASX ticker UCM Recent acquisition opens multiple near Market cap $14.4 million term revenue opportunities and product Shares on issue 71 million synergies. Cash @ 30 Dec 2013 $762k Unlisted options 6,287,500 In active strategic distribution an

  20. Slide 20: UCM - Investment

    UCM - Investment For personal use only UCM Share Price 18 17 16 15 14 12 10.5 10 8 6.7 6 4 2 0 Jan-12 2012 vwap 2013 vwap 2014* Quality assets Unrecognised value following BP+ acquisition Significant price re-alignment as revenue kicks Tightly held – difficult to buy stock 20 The measure of life www

  21. Slide 21: UCM – Investor Research

    UCM – Investor Research For personal use only Independent Research – published 13th Feb 2014 21 The measure of life www.uscom.com.au * To date FY2014

  22. Slide 22: UCM – Investor Research

    UCM – Investor Research For personal use only “……. in the hot biotech sector, Uscom appears to be flying under investors' radars.” http://www.proactiveinvestors.com.au/companies/news/52663/uscoms-central-blood-pressure-device- named-as-gold-standard-for-measurement-in-global-study-52663.html Indepen

  23. Slide 23: Next Steps

    Next Steps For personal use only • Preparation for volume manufacturing of BP+ • New distribution – 10 new discussions • Optimise distribution – US, Europe, China, Deltex • Product developments – software and interactivity 23 The measure of life www.uscom.com.au

  24. Slide 24: FY 2014 – Achievements past months

    FY 2014 – Achievements past 7 months For personal use only • Acquired Pulsecor assets - BP+ doubled company • Integrated BP+ operations • Appointed global sales manager • Preparation for BP+ manufacture • Product improvements • Regulatory approval • Licensing/distribution discussions • Signed 5yr $7

  25. Slide 25: Risks

    Risks For personal use only • Global medical markets unpredictable • Product development/regulatory slower and more costly than expected • Distribution slow to achieve revenue goals • Competitive risks • Patent breaches • Inadequate capital – time and money 25 The measure of life www.uscom.com.au

  26. Slide 26: Summary and outlook

    Summary and outlook For personal use only • Premium cardiovascular device company poised for global growth • Strategic strength in the cardiovascular monitoring space • Two platform technologies with significant unrecognised value • An established and stable business team with a global focus • Activ

  27. Slide 27: Summary and outlook: Distribution. Sales. Revenue.

    Summary and outlook For personal use only Distribution. Sales. Revenue. 27 The measure of life www.uscom.com.au

  28. Slide 28: Thank you

    For personal use only Thank you Excellent Business 28 www.uscom.com.au

Uscom — Investor Presentation (February 2014) on 6ix